# Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors

> **NCT03426254** · PHASE1 · WITHDRAWN · sponsor: **Center Trials & Treatment**

## Conditions studied

- Advanced or Recurrent Solid Tumors
- Breast Neoplasm

## Interventions

- **BIOLOGICAL:** Injections Subcutaneously Talazoparib
- **DRUG:** Oral capsules Talazoparib

## Key facts

- **NCT ID:** NCT03426254
- **Lead sponsor:** Center Trials & Treatment
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-11-10
- **Primary completion:** 2023-12-10
- **Final completion:** 2024-01-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** the company is liquidated
- **Last updated:** 2023-03-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03426254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03426254, "Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03426254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*